Specialty Pharmacy

Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses the key takeaways from the ASCO 2019 meeting and the important information that pharmacists should be aware of during the American Society of Clinical Oncology Annual Meeting in Chicago, IL

Zolgensma is the first gene therapy indicated for the treatment of children with spinal muscular atrophy.

Expanded mental health care at HIV clinics across the United States could help in reaching the goal of viral suppression among 90% of the population.

Top news of the day from across the health care landscape.

Many different strategies to achieve sustained virologic remission in HIV are being evaluated.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Obesity may increase severity of disability in patients with relapsing-remitting multiple sclerosis.

Breast cancers with somatic or germline BRCA 1/2 mutations may not be as responsive to checkpoint inhibitors as previously thought.

The FDA has accepted and set action dates for the luspatercept (Celgene and Acceleron) Biologic License Application.

Top news of the day from across the health care landscape.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Thomas Jefferson University discusses how pharmacist-led interventions help to reduce adverse events associated with polypharmacy in geriatric patients during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Galcanezumab-gnlm (Emgality, Eli Lilly) is the first calcitonin gene-related peptide antibody approved for both migraine and episodic cluster headache in adults.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, references the ENESTop 192-week study results in which treatment-free remission was achieved in patients with chronic myeloid leukemia in chronic phase after stopping second-line nilotinib.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Jefferson University, discusses how pharmacists can counsel geriatric patients who may be taking multiple medications for chronic illnesses during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

The Impassion130 trial evaluated whether atezolizumab plus nanoparticle albumin-bound paclitaxel increased overall survival in patients with triple negative breast cancer when compared to chemotherapy alone.

During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, discusses his recommendations for pharmacists who may be counseling a patient with chronic myeloid leukemia during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Popular brand-name prescription drugs have seen substantial price increases over the past 6 years, a trend that is likely to continue.

Top news of the day from across the health care landscape.

Findings presented at the 2019 ASCO meeting show venetoclax plus obinutuzumab induced deep, high, and long-lasting minimal residual disease negativity in chronic lymphocytic leukemia.

At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.

The multi-national phase 3 clinical trial on the novel drug as a treatment option for patients with advanced bladder cancer after they’ve received standard chemotherapy and immune treatments.

The National Association of Specialty Pharmacy has named Andy Slavitt, former Center for Medicare and Medicaid Services acting administrator, as the second keynote speaker for their seventh annual meeting.

Pharmacy owners should spend time reviewing marketing arrangements with an attorney who is well-versed in the anti-kickback law to avoid potential pitfalls.

Updated analysis shows favorable survival outcomes with nivolumab and ipilimumab and provides evidence of long-term survival in patients with advanced melanoma.

Top news of the day from across the health care landscape.